Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2012

View Archived Issues

Investigators discover two novel genes related to ALS

Amgen presents novel series of beta-secretase inhibitors

GeoVax presents promising phase II results for their HIV vaccines

Actelion designs novel orexin receptor antagonists

Research at Actelion yields new P2X7 receptor antagonists

Vertex Pharmaceuticals patents Na(V) channel inhibitors

University of Pittsburg presents new radioprotectants

Cystic Fibrosis Foundation Therapeutics and Pulmatrix enter collaboration

Novel PDE10A inhibitors created at Allergan

Georgetown University presents new AGBL2 inhibitors

Biodel advances with phase II insulin study

Novo-23 presented as novel antitubercular drug candidate with a new antibiotic target

RQ-00201894 selected for preclinical evaluation

DMC recommends Celsion's HEAT Study continuation

Phase III study of Japanese cedar pollinosis immunotherapy meets primary endpoint

Boehringer Ingelheim begins expanded access program for afatinib

Cornerstone Therapeutics provides regulatory update on lixivaptan

Dara BioSciences acquires exclusive U.S. right to Gelclair

Oncodesign and Sanofi enter kinase research collaboration

Treanda now available in Canada

Pearl Therapeutics identifies optimal dose of COPD treatment candidate

RepliGen withdraws MAA for SecreFlo

Investigator-sponsored stem cell study for peripheral artery disease approved in Japan

Janssen begins dosing in phase II antidepressant study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...